ABT

Abbott
NYSE

Real-time Quotes | Nasdaq Last Sale

109.50
-0.17
-0.16%
Opening 11:52 10/19 EDT
OPEN
109.90
PREV CLOSE
109.67
HIGH
111.01
LOW
109.14
VOLUME
1.60M
TURNOVER
--
52 WEEK HIGH
114.20
52 WEEK LOW
61.61
MARKET CAP
193.87B
P/E (TTM)
63.34
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
Benzinga · 23h ago
Netflix, Abbott, Chipotle Among Earnings Reports Next Week
Third-quarter earnings season kicks into high gear with tech and healthcare names among those being closely watched.
TheStreet.com · 1d ago
Stocks To Watch: GM's Hummer Charges The EV Party, Earnings Blitz
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Podcasts, Stitcher and Spotify (click the highlighted links). The earnings season heats up next week, with high-fliers Netflix (NFLX), Tesla (TSLA) and Chipotle (CMG) all reporting. Coming off the heels of a strong retail sales report, economic reports of interest in the week ahead include looks at the
Seekingalpha · 2d ago
Moody's Outlook for the US medical products and devices industry revised to positive on higher earnings, increased demand
Moody's · 2d ago
An Analyst Plays Matchmaker With Chevron and Exxon
A merger of the two oil giants would allow significant cost cutting and balance-sheet flexibility. But the differences between them could be a problem. And then there’s the name of the new company.
Barrons.com · 2d ago
Revenge Of The Clones: Roche Takes A Hit From Biosimilars, But Worthwhile Value Remains
Roche missed revenue expectations for the third quarter, with biosimilar competition returning as a meaningful negative driver for the business, but newer products continue to grow nicely.Management reiterated its full-year guidance, suggesting a stronger Q4, with the pharma business back to pre-COVID-19 levels and the diagnostics business continuing to benefit from COVID-19 testing demand.Between a stronger portfolio of new blockbuster drugs like Ocrevus, Hemlibra, and Tecentriq, and a deep pipeline, I believe Roche will generate mid-single-digit long-term FCF growth, supporting a high-$40's FV.
Seekingalpha · 3d ago
The Zacks Analyst Blog Highlights: Abbott Laboratories, NextEra Energy, Silgan Holdings, UniFirst Corp and Landstar System
The Zacks Analyst Blog Highlights: Abbott Laboratories, NextEra Energy, Silgan Holdings, UniFirst Corp and Landstar System
Zacks · 3d ago
COVID-19 Antigen Test Launch to Drive Abbott (ABT) Q3 Earnings
Abbott (ABT) is expected to register strong sales in the Adult Nutrition category, banking on growing global demand for its nutrition brand Ensure.
Zacks · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABT. Analyze the recent business situations of Abbott through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABT stock price target is 116.47 with a high estimate of 136.00 and a low estimate of 99.00.
EPS
Institutional Holdings
Institutions: 2.12K
Institutional Holdings: 1.36B
% Owned: 76.68%
Shares Outstanding: 1.77B
TypeInstitutionsShares
Increased
718
55.40M
New
101
6.33M
Decreased
843
36.28M
Sold Out
71
3.68M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.12%
Healthcare Equipment & Supplies
+0.01%
Key Executives
Chairman/Executive Director
Miles White
President/Chief Executive Officer/Chief Operating Officer/Director
Robert Ford
Chief Financial Officer/Executive Vice President - Finance
Robert Funck
Executive Vice President/General Counsel/Secretary
Hubert Allen
Executive Vice President/Director of Human Resources
Mary Moreland
Executive Vice President
John Capek
Executive Vice President
Lisa Earnhardt
Executive Vice President
John Ginascol
Executive Vice President
Andrew Lane
Executive Vice President
Daniel Salvadori
Executive Vice President
Andrea Wainer
Senior Vice President
Roger Bird
Senior Vice President
Charles Brynelsen
Senior Vice President
Jaime Contreras
Senior Vice President
Michael Dale
Senior Vice President
Sammy Karam
Senior Vice President
Joseph Manning
Senior Vice President
Michael Pederson
Senior Vice President
Christopher Scoggins
Senior Vice President
Jared Watkin
Senior Vice President
Alejandro Wellisch
Senior Vice President
Randel Woodgrift
Lead Director/Independent Director
William Osborn
Independent Director
Robert Alpern
Independent Director
Roxanne Austin
Independent Director
Sally Blount
Independent Director
Michelle Kumbier
Independent Director
Edward Liddy
Independent Director
Darren McDew
Independent Director
Nancy McKinstry
Independent Director
Phebe Novakovic
Independent Director
Samuel Scott
Independent Director
Daniel Starks
Independent Director
John Stratton
Independent Director
Glenn Tilton
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/17/2020
Dividend USD 0.36
10/14/2020
06/12/2020
Dividend USD 0.36
07/14/2020
02/21/2020
Dividend USD 0.36
04/14/2020
12/13/2019
Dividend USD 0.36
01/14/2020
09/12/2019
Dividend USD 0.32
10/11/2019
06/14/2019
Dividend USD 0.32
07/12/2019
02/22/2019
Dividend USD 0.32
04/12/2019
12/14/2018
Dividend USD 0.32
01/14/2019
09/13/2018
Dividend USD 0.28
10/12/2018
06/08/2018
Dividend USD 0.28
07/12/2018
02/16/2018
Dividend USD 0.28
04/12/2018
12/15/2017
Dividend USD 0.28
01/11/2018
09/14/2017
Dividend USD 0.265
10/12/2017
06/09/2017
Dividend USD 0.265
07/12/2017
02/21/2017
Dividend USD 0.265
04/11/2017
12/12/2016
Dividend USD 0.265
01/11/2017
09/16/2016
Dividend USD 0.26
10/12/2016
06/10/2016
Dividend USD 0.26
07/13/2016
02/19/2016
Dividend USD 0.26
04/13/2016
12/11/2015
Dividend USD 0.26
01/13/2016
09/17/2015
Dividend USD 0.24
10/13/2015
06/12/2015
Dividend USD 0.24
07/13/2015
02/20/2015
Dividend USD 0.24
04/13/2015
02/11/2015
Dividend USD 0.24
01/13/2015
09/11/2014
Dividend USD 0.22
10/10/2014
06/13/2014
Dividend USD 0.22
07/11/2014
02/21/2014
Dividend USD 0.22
04/11/2014
10/16/2013
Dividend USD 0.22
01/13/2014
09/12/2013
Dividend USD 0.14
10/10/2013
06/14/2013
Dividend USD 0.14
07/11/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABT
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Abbott Laboratories stock information, including NYSE:ABT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABT stock methods without spending real money on the virtual paper trading platform.